KRAS Mutation as Predictor Factor in Locally Advanced Rectal Cancer

作者: Flamarique Sonia , Asin Gemma , Campo M , Fernando Arias , Guerrero David

DOI: 10.31487/J.ACO.2019.03.03

关键词:

摘要: Introduction: Standard treatment of locally advanced rectal cancer (LARC) includes neoadjuvant chemo-radiotherapy followed by total mesorectal excision (TME). The role of KRAS as a biomarker in rectal cancer remains equivocal. We evaluate the Tumor Regression Grade (TRG), Relapse-Free Survival (RFS) and Overall Survival (OS) according to the KRAS oncogene status in LARC. Material and Method: We evaluated the KRAS status in 23 patients with LARC. Tumor DNA was obtained from pretreatment biopsy tissues. Results: KRAS mutation was found in 30,4% of the patients. TRG (1-2) after CRT were 56,2% and 42,8%, for wild-type and mutant KRAS groups (p= NS). After a median follow-up of 31 months, there was no difference in RFS (47,7 vs 23,3 months) or OS (51,5 vs 30 months) between wild-type and mutant-type KRAS groups, respectively. Conclusions: Although KRAS status seems to have slightly better prognosis in LARC, it does not reach significant results (probably due to insufficient sample) in TRG, RFS or OS.

参考文章(21)
Rectal cancer clinical practice guidelines in oncology. Journal of The National Comprehensive Cancer Network. ,vol. 3, pp. 492- 508 ,(2005) , 10.6004/JNCCN.2003.0007
Jeong Won Lee, Jong Hoon Lee, Byoung Yong Shim, Sung Hwan Kim, Mi-Joo Chung, Bong-Hyeon Kye, Hyung Jin Kim, Hyeon Min Cho, Hong Seok Jang, KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery Medicine. ,vol. 94, pp. e1284- ,(2015) , 10.1097/MD.0000000000001284
Marisa D. Santos, Cristina Silva, Anabela Rocha, Eduarda Matos, Carlos Nogueira, Carlos Lopes, Prognostic Value of Mandard and Dworak Tumor Regression Grading in Rectal Cancer: Study of a Single Tertiary Center International Scholarly Research Notices. ,vol. 2014, pp. 310542- 310542 ,(2014) , 10.1155/2014/310542
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
C Bengala, S Bettelli, F Bertolini, G Sartori, A Fontana, N Malavasi, R Depenni, S Zironi, C Del Giovane, G Luppi, P F Conte, Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy British Journal of Cancer. ,vol. 103, pp. 1019- 1024 ,(2010) , 10.1038/SJ.BJC.6605853
Pedro Luna-P�rez, Julia Segura, Isabel Alvarado, Sonia Labastida, H�ctor Santiago-Pay�n, Angelina Quintero, Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Annals of Surgical Oncology. ,vol. 7, pp. 727- 731 ,(2000) , 10.1007/S10434-000-0727-0
Tomoya Yokota, Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anti-cancer Agents in Medicinal Chemistry. ,vol. 12, pp. 163- 171 ,(2012) , 10.2174/187152012799014968
David Z Chang, Vikas Kumar, Ying Ma, Kuiyuan Li, Scott Kopetz, None, Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. Journal of Hematology & Oncology. ,vol. 2, pp. 18- 18 ,(2009) , 10.1186/1756-8722-2-18
Jochen Gaedcke, Marian Grade, Klaus Jung, Markus Schirmer, Peter Jo, Christoph Obermeyer, Hendrik A. Wolff, Markus K. Herrmann, Tim Beissbarth, Heinz Becker, Thomas Ried, Michael Ghadimi, KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiotherapy and Oncology. ,vol. 94, pp. 76- 81 ,(2010) , 10.1016/J.RADONC.2009.10.001